Dr. Christopher Moertel
Claim this profileUniversity of Minnesota/Masonic Cancer Center
Studies Neurofibromatosis
Studies Benign Glioma
15 reported clinical trials
24 drugs studied
Area of expertise
1Neurofibromatosis
NF1 positive
NF2 positive
Stage IV
2Benign Glioma
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Christopher Moertel is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Christopher Moertel
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Christopher Moertel has experience with
- Selumetinib
- Radiation Therapy
- Mirdametinib (PD-0325901)
- Curcumin
- High Phenolic Extra Virgin Olive Oil (HP-EVOO)
- Placebo
Breakdown of trials Christopher Moertel has run
Neurofibromatosis
Benign Glioma
Neurofibromatosis Syndrome
Spinal Cord Neurofibroma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher Moertel specialize in?
Christopher Moertel focuses on Neurofibromatosis and Benign Glioma. In particular, much of their work with Neurofibromatosis has involved NF1 positive patients, or patients who are NF2 positive.
Is Christopher Moertel currently recruiting for clinical trials?
Yes, Christopher Moertel is currently recruiting for 7 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Christopher Moertel has studied deeply?
Yes, Christopher Moertel has studied treatments such as Selumetinib, Radiation Therapy, Mirdametinib (PD-0325901).
What is the best way to schedule an appointment with Christopher Moertel?
Apply for one of the trials that Christopher Moertel is conducting.
What is the office address of Christopher Moertel?
The office of Christopher Moertel is located at: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota 55455 United States. This is the address for their practice at the University of Minnesota/Masonic Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.